RWIHX
Price
$63.52
Change
+$0.33 (+0.52%)
Updated
Dec 20 closing price
TNBRX
Price
$18.66
Change
+$0.12 (+0.65%)
Updated
Dec 20 closing price
Ad is loading...

RWIHX vs TNBRX

Header iconRWIHX vs TNBRX Comparison
Open Charts RWIHX vs TNBRXBanner chart's image
American Funds Capital World Gr&Inc R5E
Price$63.52
Change+$0.33 (+0.52%)
VolumeN/A
CapitalizationN/A
1290 SmartBeta Equity R
Price$18.66
Change+$0.12 (+0.65%)
VolumeN/A
CapitalizationN/A
RWIHX vs TNBRX Comparison Chart
Loading...
View a ticker or compare two or three
VS
RWIHX vs. TNBRX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RWIHX is a Buy and TNBRX is a Hold.

FUNDAMENTALS
Fundamentals
RWIHX has more cash in the bank: 125B vs. TNBRX (217M). RWIHX pays higher dividends than TNBRX: RWIHX (1.86) vs TNBRX (0.92). RWIHX was incepted earlier than TNBRX: RWIHX (9 years) vs TNBRX (10 years). TNBRX is a more actively managed with annual turnover of: 34.00 vs. RWIHX (27.00). TNBRX has a lower initial minimum investment than RWIHX: TNBRX (0) vs RWIHX (250). TNBRX annual gain was more profitable for investors over the last year : 14.46 vs. RWIHX (8.84). TNBRX return over 5 years is better than : 41.44 vs. RWIHX (29.56).
RWIHXTNBRXRWIHX / TNBRX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years10 years-
Gain YTD7.87513.43359%
Front LoadN/AN/A-
Min. Initial Investment2500-
Min. Initial Investment IRAN/AN/A-
Net Assets125B217M57,604%
Annual Yield % from dividends1.860.92202%
Returns for 1 year8.8414.4661%
Returns for 3 years6.7015.2344%
Returns for 5 years29.5641.4471%
Returns for 10 yearsN/A97.33-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KRON0.960.03
+3.21%
Kronos Bio
NOVT153.500.04
+0.03%
Novanta
ANIK16.31-0.02
-0.12%
Anika Therapeutics
DEO125.47-1.77
-1.39%
Diageo plc
GPCR27.90-2.07
-6.91%
Structure Therapeutics